Market News & Trends
Dipexium Pharmaceuticals Announces Issuance of Patent
Dipexium Pharmaceuticals, Inc. recently announced that the European Patent Office has issued a new Locilex patent in the European Union (EU). The patent claims are…
Crown Bioscience Launches New Translational Platforms
Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance metabolic disease and oncology research, will be announcing the release…
Capsugel Investing in Enhanced Micronization Capacity & Capabilities
Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, recently announced an expansion of its facility in Quakertown, PA, to meet increasing…
Boost Vaccination Data Encourage Continued Development of Parkinson's Vaccine
AFFiRiS AG recently announced results of AFF008A, a Phase I clinical trial to assess boost immunizations with AFFITOPE PD01A, an active vaccine against Parkinson's disease…
Fuji Health Science Announces Name Change
Fuji Health Science, Inc. recently announced that as of September 1, 2016, the name of the entity has become Fuji Chemical Industries USA, Inc. to…
Allergan Acquires Gene Therapy Company
Allergan plc recently announced it has acquired substantially all of the assets of RetroSense in an all-cash transaction. Under the terms of the transaction, Allergan…
Niagara University Faculty Present Groundbreaking Research, New Insulin Pill For Diabetes Patients
NIAGARA UNIVERSITY, N.Y. - The need for painful insulin injections by certain diabetes patients may be eliminated with the introduction of a new technique…
Results From Preclinical Research & Phase Ib Study of Biogen’s Investigational Alzheimer’s Disease Treatment Published
Results from preclinical research and PRIME, the Phase Ib study of Biogen’s investigational treatment for early Alzheimer’s disease (AD), aducanumab, were published in a recent…
SteadyMed Announces Completion of Pre-NDA Submission Manufacturing Activities
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery…
SGS Opens New Dedicated Facility for Extractables & Leachables Testing
SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, recently announced it has opened a new facility in Wiesbaden, Germany, exclusively to offer extractables…
Dalton Announces Completion of a Major Expansion in Sterile Filling & API Manufacturing
Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical and biotechnology companies, recently announced the completion of a $5-million expansion in…
Cytokinetics & Amgen to Advance Drug to Phase III Clinical Development
Cytokinetics, Inc. recently announced the advancement of omecamtiv mecarbil to Phase III clinical development with a cardiovascular outcomes clinical trial expected to initiate in the…
Avantor Performance Materials & NuSil Technology to Merge
Avantor Performance Materials and NuSil Technology LLC, both portfolio companies of New Mountain Capital LLC, have signed a definitive agreement to merge. This merger will…
Aptar Pharma Announces Development & License Agreement With BD
Aptar Pharma Announces Development & License Agreement With BD Aptar Pharma, a leading drug delivery solutions provider and segment of AptarGroup, Inc.…
CordenPharma Chenôve Receives Successful FDA Inspection
CordenPharma is pleased to announce that their CordenPharma Chenôve (France) manufacturing facility recently completed an FDA Inspection and received a successful response with no…
Novel Gene Therapy Drug for Huntington's Disease Reported
Data from Vybion on a novel treatment for Huntington's disease has been published in the Journal of Neurodegenerative diseases. The published study (http://www.hindawi.com/journals/jnd/2016/7120753/) links the…
Stemline Therapeutics Receives Breakthrough Therapy Designation
Stemline Therapeutics, Inc. recently announced that the US FDA has granted Breakthrough Therapy Designation to SL-401, a targeted therapy directed to the interleukin-3 receptor (CD123),…
Idera Pharmaceuticals Presents Novel Mechanism of Action of its Third- Generation Antisense Technology
Idera Pharmaceuticals, Inc. recently announced the presentation of new preclinical data that demonstrates the novel gene-silencing mechanism of action of the third-generation antisense (3GA) technology…
Hemispherx Biopharma Announces Major Breakthrough
Hemispherx Biopharma, Inc. recently announced it has received approval of its New Drug Application (NDA) from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT)…
BioTelemetry Agrees to License Proprietary Technology to Bloom Technologies
BioTelemetry, Inc. recently announced it has entered into a strategic partnership with Bloom Technologies, Inc. Under the terms of the agreement, Bloomlife will pay BioTelemetry…
